CVKD vs FCX · $20.2M cap vs P/E 38, rev $13.26B
Cadrenal Therapeutics, Inc. Common Stock (CVKD) versus Freeport-McMoran Copper & Gold Inc (FCX) — a side-by-side from cached financials, not a winner call.
Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a biotechnology company listed on US.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
CVKD does not have a complete income-statement cache yet.
Latest reported FCX revenue for 2026-06-30 was $13.26B. Net income was $1.86B. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
CVKD currently screens at market cap $20.2M. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Not investment advice. Open the CVKD and FCX stock pages for the full models.
Not investment advice.